57728-61-7

Usage

Uses

Used in Pharmaceutical Industry:
(3-METHOXY-BENZOYLAMINO)-ACETIC ACID is used as a building block for the synthesis of various pharmaceutical and biologically active compounds. Its unique structure and properties make it a valuable component in the development of new drugs for the treatment of various diseases.
Used in Antibacterial Applications:
(3-METHOXY-BENZOYLAMINO)-ACETIC ACID is used as an antibacterial agent, exhibiting potential activity against various types of bacteria. Its ability to inhibit bacterial growth and proliferation makes it a promising candidate for the development of new antibiotics.
Used in Antifungal Applications:
(3-METHOXY-BENZOYLAMINO)-ACETIC ACID is used as an antifungal agent, showing potential activity against various types of fungi. Its ability to inhibit fungal growth and proliferation makes it a promising candidate for the development of new antifungal drugs.
Used in Drug Development Research:
(3-METHOXY-BENZOYLAMINO)-ACETIC ACID is used as a precursor in the preparation of various pharmaceutical products. Its potential therapeutic applications are being studied, particularly in the development of new drugs for the treatment of various diseases. Further research is needed to fully understand its potential uses and applications in this field.

InChI:InChI=1/C10H11NO4/c1-15-8-4-2-3-7(5-8)10(14)11-6-9(12)13/h2-5H,6H2,1H3,(H,11,14)(H,12,13)/p-1

Upstream product

• 1711-05-3 m-anisoyl chloride 
• 56-40-6 glycine 

Downstream Products

• 110194-57-5 4-[3-(4-dimethylamino-phenyl)-allylidene]-2-(3-methoxy-phenyl)-4H-oxazol-5-one 
• 299439-08-0 C₆H₅CH((C₃NO)O)C₆H₄(OCH₃) 
• 1426830-27-4 ethyl 2-(3-methoxyphenyl)-1H-imidazole-5-carboxylate 
• 782503-73-5 2-methyl-4-(2-methoxyphenylmethylene)-5(4H)-oxazolone 
• 1019201-46-7 (E)-4-(2-methoxybenzylidene)-2-methyloxazol-5(4H)-one 

Relevant academic research and scientific papers

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Synthesis of di- and tri-substituted imidazole-4-carboxylates via PBu3-mediated [3+2] cycloaddition

Some new di- and trisubstituted imidazole-4-carboxylates were prepared from amidoacetic acids 3 in the present report. The key step to establish such imidazole- 4-carboxylates stemmed from the PBu3-mediated [3+2] cycloaddition between in situ-generated Δ2-oxazolinone 4 and ethyl cyanoformate6. Our results indicated that trisubstituted imidazoles 7-20 were afforded in better yields than those of disubstituted imidazoles 21-27. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications1 to view the free supplemental file. Copyright Taylor & Francis Group, LLC.

Novel affinity ligands for chromatography using combinatorial chemistry

Spatially addressable combinatorial libraries were synthesized by solution phase chemistry and screened for binding to human serum albumin. Members of arylidene diamide libraries were among the best hits found, having submicromolar binding affinities. The results were analyzed by the frequency with which particular substituents appeared among the most potent compounds. After immobilization of the ligands either through the oxazolone or the amine substituent, characterization by surface plasmon resonance showed that ibuprofen affected the binding kinetics, but phenylbutazone did not. It is therefore likely that these compounds bind to Site 2 in sub domain IIIA of human serum albumin (HSA).

4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof

Compound corresponding to the general formula (I) in which R1, R2, R3, R4 and R5 each represent a hydrogen or halogen atom or a nitro, amino, trifluoromethyl, trifluoroalkoxy, cyano, hydroxyl, (C